MBG novel therapeutics series
Join us Mondays at 4:30PM to hear from biotech professionals about novel therapeutics, which revolutionized pharma over the last decade. In this seminar series, industry leaders provide an overview of the development process for various classes of biologics, from fusion proteins to CAR-T cells, mRNA vaccines, siRNA therapeutics, and more.
| 9/21 | Amgen | Roger Hart | Scientific Director, Process Development | Overview of Drug Modalities |
| 9/28 | Amgen | Cen Xu | Scientific Director, Neuroscience | The Science Behind Aimovig |
| 10/19 | Moderna | Andrea Carfi | Head of Research, Infectious Disease | Development of mRNA Medicines |
| 10/26 | Alnylam | Eric Green | Senior Vice President, TTR Franchise | siRNA Therapeutics |
| 11/2 | Beam | Adam Hartigan | Director of Hematology | CRISPR Therapies |
| 11/9 | Vertex | Paul Negulescu | Director of San Franscisco Research Site | Cystic Fibrosis Combination Therapies |
| 11/16 | Novartis | Jennifer Brogdon | Exec. Director, Head of Cell Therapy Research | Cell Therapies |
| 11/23 | Synlogic/Ginkgo | David Lubkowicz, Christian Ridley | Lead Strain Engineer at Synlogic, Program Lead in Organism Engineering at Ginkgo | Synthetic Biology Therapies |
| 11/30 | Vertex | Angela Yen | Leader of Cell and Genetic Therapies Group | Gene Therapies |
| TBA | Amgen | Panelists | Various | Careers in Biotech |
RSVP: https://forms.gle/25upmPB6ZLf9xxJ87
Zoom link: https://tinyurl.com/y6z6a6fb
Recent Comments